

**IN THE CLAIMS:**

Please amend the claims as follows:

1. (Currently amended) A pharmaceutical composition characterized by ~~either tinidazole and fluconazole and/or a an esterisomer stereoisomer or a an acceptable esterisomerie stereoisomeric mixture thereof~~, comprising from about 50 to less than 150 mg fluconazole and from about 1000 to less than 2000 mg tinidazole.
2. (Currently amended) A pharmaceutical composition characterized by secnidazole and fluconazole or a stereoisomer or a stereoisomeric mixture thereof, comprising from about 50 to less than 150 mg of fluconazole and from about 1000 to less than 2000 mg of secnidazole.
3. (Currently amended) The pharmaceutical composition according to Claim 2, characterized by a percent by weight of 75%  $\pm$  20% secnidazole fluconazole and a percent by weight of 6%  $\pm$  2% 6%  $\pm$  20% of fluconazole secnidazole.
4. (Currently amended) The pharmaceutical composition according to Claim 3, characterized by oral administration.
5. (Previously presented) The pharmaceutical composition according to Claim 3, characterized by a tablet form.
6. (Previously presented) The pharmaceutical composition according to Claim 2, characterized by a vehicle mixture of acceptable pharmaceutical vehicles that comprises microcrystalline cellulose, sodium glycolate of starch, polyvinylpyrrolidone, magnesium stearate and white opadry.

7. (Withdrawn) A method for the treatment of infectious diseases in the female reproductive system, comprising giving a patient suffering such a disease a single dose per day of the pharmaceutical composition of Claim 2.

8. (Withdrawn) A method for the treatment of infectious diseases with the pharmaceutical composition of Claim 7, characterized because wherein the infectious disease has been caused by *Gardnerella Vaginalis*, *Astinomyces*, *Candida*, *Micrococcus*, yeast, *Proteus*, *Micrococcus*, *E.Coli*, *Trichomonas Vaginilis* or *Trichomonas V*.

9. (Withdrawn) The method according to claim 8, characterized by providing the pharmaceutical composition in a tablet form.

10. (Withdrawn) The method according to Claim 7 characterized by the fact that the pharmaceutical composition is administered in a single dose containing approximately 112.5 mg of fluconazole and approximately 1.5 g of tinidazole.

11. (Withdrawn) The use of the pharmaceutical compounds of Claim 1, wherein the active ingredients are from 100 to less than 150 mg of fluconazole and from 100 to less than 2000 mg of tinidazole for the preparation of a medication useful in the treatment of infectious diseases in the female reproductive system.

12. (Withdrawn) The use according to claim 11, wherein the pharmaceutical compound comprises 112.5 mg of fluconazole and 1.5 g of tinidazole.

13. (NEW) The pharmaceutical composition according to Claim 1, characterized by a percent by weight of  $75\% \pm 20\%$  tinidazole and a percent by weight of  $6\% \pm 2\%$  fluconazole.

14. (NEW) The pharmaceutical composition according to Claim 13, characterized by oral administration.

15. (NEW) The pharmaceutical composition according to Claim 14, characterized by a tablet form.

16. (NEW) The pharmaceutical composition according to Claim 1, characterized by a vehicle mixture of acceptable pharmaceutical vehicles that comprises microcrystalline cellulose, sodium glycolate of starch, polyvinylpyrrolidone, magnesium stearate and white opadry.

17. (NEW) The pharmaceutical composition according to Claim 1, characterized by a percent by weight of 75% tinidazole.

18. (NEW) The pharmaceutical composition according to Claim 2, characterized by a percent by weight of 75% secnidazole.

19. (NEW) The pharmaceutical composition according to Claim 1, characterized by a percent by weight of 5.7% fluconazole.

20. (NEW) The pharmaceutical composition according to Claim 2, characterized by a percent by weight of 5.7% fluconazole.

21. (NEW) The pharmaceutical composition according to Claim 1, wherein the composition is characterized by about 112.5 mg of fluconazole and about 1.5 g of tinidazole.

22. (NEW) The pharmaceutical composition according to Claim 2, wherein the composition is characterized by about 112.5 mg of fluconazole and about 1.5 g of secnidazole.